大麻醇在发育中的大脑中增强了因巴比诱导的细胞死亡
Rubia Aparecida Fernandes1, João Vitor Melo Ribeiro2, Rodrigo Espindula Torres1
1Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Brazil.
Neurotoxicology
|July 9, 2025
概括
大麻 (CBD) 单独在年轻的老鼠中没有神经毒性,但将其与 (PB) 结合起来显著增加了神经元死亡. 建议在使用CBD与PB治疗儿科时谨慎使用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 儿科神经学 儿科神经学
背景情况:
- 影响全球人口的1%,儿童患病率更高.
- (Phenobarbital,PB) 是用于小儿的常见抗发作药物 (ASM),但仅在三分之二的病例中有效,并可能导致神经毒性.
- Cannabidiol (CBD) 是一种有前途的替代ASM,副作用较少,神经保护能力较强,但其对发育中的大脑的安全性尚不清楚.
研究的目的:
- 评估大麻 (CBD) 在未成熟的动物大脑中的安全性.
- 为了评估CBD使用-玉C染色的潜在神经退行性影响.
- 研究CBD和Phenobarbital (PB) 对发育中的大脑神经元细胞死亡的联合作用.
主要方法:
- 未成熟的Wistar大鼠 (产后第7天) 接受了2,20和200毫克/公斤的CBD剂量.
- 24小时后,通过使用-玉C体质化学染色来评估神经细胞死亡.
- 一组组合组接受了CBD (30 mg/kg) 与PB (75 mg/kg) 以评估协同作用的神经毒性作用.
主要成果:
- 与所有测试剂量中的对照组相比,单独使用CBD并没有增加神经元细胞死亡.
- 结合CBD (30 mg/kg) 和PB (75 mg/kg) 显著增加了神经元死亡.
- 在PB+CBD组合组中,PB单独观察到的神经退行症的数量是PB的两倍多.
结论:
- 在未成熟的动物大脑中,CBD在测试剂量中作为单一疗法似乎是安全的.
- 当CBD与PB联合使用时,可能会加剧PB诱导的神经毒性,可能会否定其神经保护作用.
- 在将CBD与PB结合用于儿科治疗时,由于潜在的神经毒性增加,需要采取临床谨慎.
相关概念视频
Antiepileptic Drugs: GABAergic Pathway Potentiators
665
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
665
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
371
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
371
Sedatives and Hypnotics Drugs: Barbiturates
504
Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A...
504
Antiepileptic Drugs: Potassium Channel Activators
283
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
283
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
456
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
456
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
340
Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
340


